A Study of Azacitidine in Participants With International Prognostic Scoring System (IPSS) Intermediate-2 and High-risk Myelodysplastic Syndromes (MDS), or Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)

Clinical trial NCT05218902 · COMPLETED

Trial details

NCT number: NCT05218902
Sponsor: Bristol-Myers Squibb
Status: COMPLETED
Study type: OBSERVATIONAL

Myelodysplastic Syndromes Leukemia, Myelomonocytic, Chronic Leukemia, Myeloid, Acute

Start date: 2022-02-25
Primary completion: 2023-03-20
Enrollment: 290

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.